NCT04859244View on ClinicalTrials.gov

First-in-Human Study of Orally Administered GS-441524 for COVID-19

PHASE1CompletedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

January 1, 2021

Primary Completion Date

May 1, 2021

Study Completion Date

August 1, 2021

Conditions
COVID-19
Interventions
DRUG

GS-441524

750 mg administered as a solution

Trial Locations (1)

77054

Copycat Sciences Study Site, Houston

Sponsors
All Listed Sponsors
lead

Copycat Sciences LLC

INDUSTRY

NCT04859244 - First-in-Human Study of Orally Administered GS-441524 for COVID-19 | Biotech Hunter | Biotech Hunter